Marksans Pharma shareholders and shareholding pattern
NSE: MARKSANSBSE: 524404Pharmaceuticals & BiotechnologySmall Cap
Marksans Pharma Limited · Formerly Tasc Pharmaceuticals · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1994 on BSE, Jan 2002 on NSE
Last close ₹306.20down ₹9.15 (2.90%)BSE ₹306.65
Share price at the NSE close on 30 Oct 2026. Previous close ₹315.35.
30 Oct: open ₹317.00, high ₹317.35, low ₹304.90
52-week range of traded prices to 30 Oct 2026
₹155.00Low, 30 Mar 2026₹350.95High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹13,876 Cr592nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.85
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.59
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.29%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 17.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 19.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 12,10,63344.3% delivered
Marksans Pharma's shareholding pattern for Sep 2026, filed on 15 Oct 2026, with every filing from Dec 2016: who owns its shares by group, its promoters by name and its public holders of 1% or more.
Who owns Marksans Pharma, filing by filing
Per cent of the company's shares.
Sep 2026 filing
- Promoters43.87%
- Foreign institutions19.06%
- Indian institutions5.54%
- Individuals and others31.53%
Shareholding pattern, per cent, from Sep 2022
- Promoters
- Foreign institutions
- Indian institutions
- Individuals and others
| Per cent | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.60% | 49.00% | 43.85% | 43.85% | 43.85% | 43.85% | 43.85% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | |
| Indian promoters | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.25% | 48.60% | 49.00% | 43.85% | 43.85% | 43.85% | 43.85% | 43.85% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% |
| Public. Every shareholder outside the promoter group, the employee trusts and the shares held against depositary receipts, as the filing totals them. Public in the glossary | 51.75% | 51.75% | 51.75% | 51.75% | 51.75% | 51.75% | 51.75% | 51.75% | 51.75% | 51.75% | 51.75% | 51.75% | 51.75% | 51.75% | 51.75% | 51.75% | 51.75% | 51.75% | 51.75% | 51.75% | 51.75% | 51.75% | 51.75% | 51.40% | 51.00% | 56.15% | 56.15% | 56.15% | 56.15% | 56.15% | 56.13% | 56.13% | 56.13% | 56.13% | 56.13% | 56.13% | 56.13% | 56.13% | 56.13% | 56.13% |
| Shares in issue | 40,93,13,698 | 40,93,13,698 | 40,93,13,698 | 40,93,13,698 | 40,93,13,698 | 40,93,13,698 | 40,93,13,698 | 40,93,13,698 | 40,93,13,698 | 40,93,13,698 | 40,93,13,698 | 40,93,13,698 | 40,93,13,698 | 40,93,13,698 | 40,93,13,698 | 40,93,13,698 | 40,93,13,698 | 40,93,13,698 | 40,93,13,698 | 40,93,13,698 | 40,93,13,698 | 40,93,13,698 | 40,93,13,698 | 40,63,57,365 | 40,30,34,114 | 45,31,63,746 | 45,31,63,746 | 45,31,63,746 | 45,31,63,746 | 45,31,63,746 | 45,31,63,746 | 45,31,63,746 | 45,31,63,746 | 45,31,63,746 | 45,31,63,746 | 45,31,63,746 | 45,31,63,746 | 45,31,63,746 | 45,31,63,746 | 45,31,63,746 |
| Shares locked inShares locked in. Shares the filing reports as barred from sale until a set day, such as promoters' shares after a public issue or shares allotted to an investor directly. Shares locked in in the glossary | – | – | – | – | – | – | – | – | – | – | – | 1,000 | – | – | – | – | – | – | 19,74,91,553 | 19,74,91,553 | 19,74,91,553 | 0 | 0 | 0 | 0 | 5,03,24,324 | 5,03,24,324 | 5,03,24,324 | 5,03,24,324 | 10,00,000 | 10,00,000 | 10,00,000 | 10,00,000 | 10,00,000 | 10,00,000 | 10,00,000 | 10,00,000 | – | – | – |
| Promoters' shares locked in | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 19,74,91,553 | 19,74,91,553 | 19,74,91,553 | 0 | 0 | 0 | 0 | 10,00,000 | 10,00,000 | 10,00,000 | 10,00,000 | 10,00,000 | 10,00,000 | 10,00,000 | 10,00,000 | 10,00,000 | 10,00,000 | 10,00,000 | 10,00,000 | – | – | – |
Filings before Sep 2022 are on an older form, which did not split institutions into foreign and Indian and grouped some holders differently, so those columns show only the lines both forms state alike. A dash is a line the filing did not state. “Under 0.01%” is a holding of shares too small to show at two decimals.
Marksans Pharma promoters
Promoters are the founders, families and companies that control the company, as its filings name them. Every member of the promoter group holding shares in the filing for Sep 2026; the largest is MARK SALDANHA, 43.80%.Promoter buying and selling
| Holder | ||
|---|---|---|
| MARK SALDANHAIndividuals and Hindu undivided families | 43.80% | 19,84,91,553 |
| Schenelle Megan SaldanhaIndividuals and Hindu undivided families | 0.03% | 1,45,000 |
| SANDRA SALDANHAIndividuals and Hindu undivided families | 0.02% | 1,02,183 |
| Merrill Jean SaldanhaIndividuals and Hindu undivided families | 0.01% | 63,273 |
| Marise Ann SaldanhaIndividuals and Hindu undivided families | 0.00% | 20,000 |
No promoter shares are reported as pledged.
Largest public holders of Marksans Pharma, filing by filing
Per cent, on the same shares as the split above.Mutual funds holding Marksans Pharma
| Holder | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ORBIMED ASIA IV MAURITIUS FVCI LIMITEDForeign direct investment | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 10.88% | 10.88% | 10.88% | 10.88% | 10.88% | 10.88% | 10.88% | 10.88% | 10.88% | 8.62% | 8.62% | 8.62% | 8.62% | 8.62% | 8.62% |
| MASSACHUSETTS INSTITUTE OF TECHNOLOGYForeign portfolio investors, category I | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 2.32% | 2.32% | 2.32% | 2.32% | 2.32% | – | – | – | – | – |
| MUKUL MAHAVIR AGRAWALResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.22% | 1.22% | 1.22% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| MUKUL MAHAVIR PRASAD AGRAWALResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | 1.03% | 1.59% | 1.71% | 1.86% | 1.86% | 1.86% | 1.88% | 1.95% | 1.95% | 1.95% | 1.95% | 1.95% | 1.47% | 1.47% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| ASHISH KACHOLIAResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.25% | 1.25% | 1.25% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| MONDRIAN EMERGING MARKET SMALL CAP EQUITY FUND, L.P.Other Institutions | 2.68% | – | – | 1.64% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| ONTARIO PENSION BOARDS- MONDRIAN INVESTMENT PARTNERS LIMITEDInstitutions Foreign Portfolio Investor | – | – | – | 1.15% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| MONDRIAN EMERGING MARKET SMALL CAP EQUITY FUNDOther Institutions | – | 2.48% | 2.29% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| ONTARIO PENSION BOARD - MONDRIAN INVESTMENT PARTNER LIMITEDInstitutions Foreign Portfolio Investor | 1.15% | 1.15% | 1.15% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| WASATCH EMERGING MARKETS SMALL CAP FUNDInstitutions Foreign Portfolio Investor | 1.52% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| CALIFORNIA PUBLIC EMPLOYEES' RETIREMENT SYSTEM, MANAGED BY WASATCH ADVISORS, INC.Institutions Foreign Portfolio Investor | 1.12% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
A filing names every holder above one per cent, in the company's own words: an insurer's holding can carry one of its funds' names. Mutual funds are left out here: each fund's holding is on the Mutual funds tab, from its own portfolio. A dash is a filing that did not name the holder, which includes holding under one per cent.